Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$13.93
+1.1%
$14.32
$8.38
$20.76
$2.23B2.161.94 million shs1.91 million shs
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
$8.34
-6.3%
$6.56
$4.34
$9.53
$535.11M0.37332,158 shs346,765 shs
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
$9.78
+0.7%
$9.04
$6.23
$16.44
$2.14B0.935.38 million shs1.19 million shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$58.03
+3.2%
$53.93
$19.00
$60.08
$2.35B0.61270,227 shs53,233 shs
7 Stocks to Buy And Hold Forever Cover

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-3.43%-1.85%-6.95%-20.35%+37.39%
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
+26.96%+27.87%+36.09%+54.78%+50.34%
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
+2.97%+4.18%+14.37%+13.57%+25.61%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
+2.46%+3.59%+1.30%+37.17%+187.97%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$13.93
+1.1%
$14.32
$8.38
$20.76
$2.23B2.161.94 million shs1.91 million shs
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
$8.34
-6.3%
$6.56
$4.34
$9.53
$535.11M0.37332,158 shs346,765 shs
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
$9.78
+0.7%
$9.04
$6.23
$16.44
$2.14B0.935.38 million shs1.19 million shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$58.03
+3.2%
$53.93
$19.00
$60.08
$2.35B0.61270,227 shs53,233 shs
7 Stocks to Buy And Hold Forever Cover

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-3.43%-1.85%-6.95%-20.35%+37.39%
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
+26.96%+27.87%+36.09%+54.78%+50.34%
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
+2.97%+4.18%+14.37%+13.57%+25.61%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
+2.46%+3.59%+1.30%+37.17%+187.97%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
2.63
Moderate Buy$19.4339.46% Upside
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
2.40
Hold$21.50157.73% Upside
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
2.79
Moderate Buy$23.78143.23% Upside
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.43
Hold$42.40-26.93% Downside

Current Analyst Ratings Breakdown

Latest AURA, PAHC, ADPT, and OCUL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/6/2026
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
Reiterated RatingBuy
5/6/2026
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
Reiterated RatingBuy$21.00
5/6/2026
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
Reiterated RatingBuy$22.00
5/6/2026
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
Reiterated RatingOutperform$30.00 ➝ $30.00
4/29/2026
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
Boost Price TargetBuy$22.00 ➝ $24.00
4/21/2026
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
Reiterated RatingSell (D-)
4/20/2026
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
Reiterated RatingSell (D-)
4/15/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Initiated CoverageNeutral$62.00
4/15/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Initiated CoverageHold$62.00
4/13/2026
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
Reiterated RatingBuy$21.00
3/30/2026
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
Reiterated RatingBuy$22.00
(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$276.98M8.04N/AN/A$1.47 per share9.48
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/AN/AN/AN/A$2.16 per shareN/A
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
$51.95M41.19N/AN/A$3.07 per share3.18
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.30B1.81$3.47 per share16.73$7.05 per share8.23
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-$59.50M-$0.40N/AN/AN/A-21.48%-46.68%-18.55%N/A
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-$106.19M-$1.79N/AN/AN/AN/A-71.25%-59.06%5/21/2026 (Estimated)
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
-$265.94M-$1.44N/AN/AN/A-511.90%-70.68%-50.53%N/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$48.26M$2.2525.7917.690.846.29%38.28%8.37%5/6/2026 (Estimated)

Latest AURA, PAHC, ADPT, and OCUL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/21/2026Q1 2026
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-$0.40N/AN/AN/AN/AN/A
5/6/2026Q3 2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.72N/AN/AN/A$367.02 millionN/A
5/5/2026Q1 2026
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-$0.16-$0.13+$0.03-$0.13$61.03 million$70.87 million
5/5/2026Q1 2026
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
-$0.32-$0.40-$0.08-$0.40$12.72 million$10.79 million
3/30/2026Q4 2025
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-$0.43-$0.37+$0.06-$0.37N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
N/AN/AN/AN/AN/A
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/AN/AN/AN/AN/A
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.480.83%N/A21.33%N/A

Latest AURA, PAHC, ADPT, and OCUL Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/5/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.120.85%6/3/20266/3/20266/24/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
N/A
3.34
3.23
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/A
8.15
8.15
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
0.11
15.39
15.32
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.14
3.05
1.22

Institutional Ownership

CompanyInstitutional Ownership
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
99.17%
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
96.75%
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
59.21%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
99.34%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
790159.76 million150.66 millionOptionable
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
5064.20 million60.16 millionNot Optionable
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
230218.91 million212.69 millionOptionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2,47540.53 million20.22 millionOptionable

Recent News About These Companies

Phibro Animal Health (NASDAQ:PAHC) CEO Sells $371,430.40 in Stock

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Adaptive Biotechnologies stock logo

Adaptive Biotechnologies NASDAQ:ADPT

$13.93 +0.15 (+1.10%)
As of 12:45 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Aura Biosciences stock logo

Aura Biosciences NASDAQ:AURA

$8.34 -0.56 (-6.27%)
As of 12:45 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Ocular Therapeutix stock logo

Ocular Therapeutix NASDAQ:OCUL

$9.78 +0.07 (+0.68%)
As of 12:45 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$58.02 +1.79 (+3.17%)
As of 12:45 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.